NAFLD/ NASH Models
Creative Animodel is a professional biopharmaceutical company dedicated to providing preclinical in vivo pharmacology services for your drug candidate. With years of experience and advanced technology platform, we have successfully established a variety of nonalcoholic fatty liver disease (NAFLD) models to help our customers promote their drug development. Our scientists have deep expertise to guarantee the high-quality services with competitive price and fast turnaround time.
What Is NAFLD?
NAFLD is a condition in which excess fat accumulates in the liver of a patient without a history of alcohol abuse. There are various factors that can contribute to NAFLD, including diet, overweight, insulin resistance, a sedentary lifestyle, as well as genetic factors. NAFLD can be classified into two major types: simple steatosis and nonalcoholic steatohepatitis (NASH). NASH is considered as the most severe type of NAFLD. In NASH, not only steatosis but also intralobular inflammation and hepatocellular ballooning are present, often accompanied by progressive fibrosis. Long-standing NASH may progress to liver cirrhosis, and hepatocellular carcinoma (HCC) may be an outcome.
Figure 1. The differences between healthy Liver and fatty liver
The morbidity of NAFLD has been increasing worldwide over recent decades in line with the increased prevalence of obesity, type 2 diabetes, and hyperlipemia. NAFLD/NASH is currently regarded as the most common chronic liver disease worldwide. It is estimated that about 20% of all adults have NAFLD and 2%-3% of adults have NASH. However, there is still no regulatory agency-approved pharmacotherapy for NAFLD/NASH, with a lack of detailed knowledge of the underlying mechanisms. Further research on pathogenic pathways and potential drug treatments is crucial, given the rapid growth in NAFLD prevalence.
Our NAFLD/NASH models
Creative Animodel offers professional preclinical pharmaceutical services with extensive expertise based on the following super-class NAFLD/NASH models:
• High‐fat diet (HFD) model
The association between NAFLD/NASH and obesity leads to the development of an HFD that matches modern Western diets. Feeding animal with a diet composed of 71% fat, 11% carbohydrates and 18% protein for 3 weeks, we have successfully established HFD induced NAFLD/NASH model. This model mimics clinically relevant features of NAFLD over a prolonged period of time.
• Methionine and choline deficient (MCD) model
The MCD is a widely employed diet in NAFLD/NASH animal studies. MCD diet is high in sucrose (40% sucrose) and fat (10% fat), and is deficient in methionine and choline, which are essential for hepatic β oxidation and the production of very low density lipoprotein (VLDL). MCD diet induced model shows the features of NASH-related inflammation and fibrosis that have been implicated in human NASH progression.
• Genetic Models
We have a variety of genetic mice models which show more characteristics of human metabolic syndrome than diet models. When fed a standard diet without an additional stimulus, these mice are useful models of NAFLD, as they develop pronounced hepatic steatosis. With the addition of a second stimulus such as an MCD diet, those models can also be used to study the progression of steatosis to NASH. Our genetic models include db/db mice, ob/ob mouse and SREBP-1c transgenic mice.
Creative Animodel provides preclinical efficacy, proof-of-concept, and mechanism of action services based on our well-characterized models for your drug candidates. We work closely with our customers to offer scientific guidance in model selection, customized study design, and end-point analysis and assist you with professional interpretation of the data. If you have any questions, please feel free to contact us.